Format

Send to

Choose Destination
Clin Immunol. 2017 Jul;180:100-105. doi: 10.1016/j.clim.2017.05.009. Epub 2017 May 10.

Genetic modifiers of multiple sclerosis progression, severity and onset.

Author information

1
Department of Medical Genetics, University of British Columbia, Vancouver, Canada; Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
2
Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
3
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
4
Department of Medical Genetics, University of British Columbia, Vancouver, Canada. Electronic address: carles@can.ubc.ca.

Abstract

The genetic contribution to clinical outcomes for multiple sclerosis (MS) has yet to be defined. We performed exome sequencing analysis in 100 MS patients presenting opposite extremes of clinical phenotype (discovery cohort), and genotyped variants of interest in 2016 MS patients (replication cohort). Linear and logistic regression analyses were used to identify significant associations with disease course, severity and onset. Our analysis of the discovery cohort nominated 38 variants in 21 genes. Replication analysis identified PSMG4 p.W99R and NLRP5 p.M459I to be associated with disease severity (p=0.002 and 0.008). CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p=0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p=0.031 and 0.023). In addition, PSMG4 p.W99R and NLRP5 p.R761L were found to correlate with an earlier age at MS clinical onset, and MC1R p.R160W with delayed onset of clinical symptoms (p=0.010-0.041).

KEYWORDS:

Association; Genetic; Multiple sclerosis; Progression; Severity

PMID:
28501589
DOI:
10.1016/j.clim.2017.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center